News Feature

Chemical proteomics has brought rigor to covalent drug discovery and drugs to the clinic. Can it deliver a new generation of drug targets?

Today’s uniquely challenging biotech climate may result in a more resilient sector.

As the next generation of spatial transcriptomics tools hits the market, researchers are uncovering previously unknown interactions that could transform clinical research.

Developers are recombining or sharpening established drugs, molecules and mechanisms to create a new generation of neurology therapies.

After two volatile years, FDA approvals in 2024 settled closer to their 10-year average. Will nominated commissioner Marty Makary shake things up, or maintain a steady ship?

Merger and acquisition activity is at a seven-year low in 2024 as buyers digest prior deals and US election jitters delayed further spending. Expect a pick-up in 2025.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Gate Bioscience wants to tailor gates that stop problematic proteins at the source.

Precision genetic methods are enabling more efficient, environmentally friendly pest control methods for agricultural use as well as stopping the spread of disease.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Switch Therapeutics is rethinking cell-type specificity, building precision RNAi therapeutics for the brain.

Bacteria, fungi and plants can be grown and engineered to remove plastics, chemicals and pollutants from contaminated soil and water.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Atomic AI generates the structure data it needs for its AI model with the aim of RNA drug discovery.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. A rescued chimeric antigen receptor from Cargo Therapeutics for hard-to-treat lymphomas shows promise in patients while a trispecific advances toward human testing.

After a difficult three years, biotech financing may slowly be returning to health.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Unnatural Products is rewriting the rules for potent oral therapies.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Empress Therapeutics is reverse-engineering microbial manufacturing.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tenpoint Therapeutics optimizes delivery and generation of stem-cell-derived retinal cells for vision repair.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tome Biosciences inserts large DNA sequences into precise genomic locations, overcoming limitations of base and prime editing.

Targeted radiopharmaceuticals offer resistance-free potency, pre-treatment imaging and widespread combination potential. Big pharma and investors are piling in.

An upsurge in biotechs focused on women’s health responds to a fresh understanding of female biology to develop new tools and treatments.